Protection of hamsters challenged with SARS-CoV-2 after two doses of MVC-COV1901 vaccine followed by a single intranasal booster with nanoemulsion adjuvanted S-2P vaccine

Article Multidisciplinary Sciences

SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters

Peter J. Halfmann et al.

Summary: The recent study by the SAVE/NIAID network shows that the B.1.1.529 Omicron variant causes milder lung disease in rodents, which is consistent with preliminary human clinical data.

NATURE (2022)

Add to Collection

Article Immunology

Hamsters Protected from SARS-CoV-2 Delta Variant Challenge after Two Doses of Adjuvanted SARS-CoV-2 Recombinant Spike Protein (S-2P) and One Dose of Beta S-2P

Tsun-Yung Kuo et al.

Summary: The study shows that two doses of adjuvanted recombinant SARS-CoV-2 vaccine followed by a booster dose can provide broad-spectrum neutralization and protect hamsters from the delta variant challenge.

JOURNAL OF INFECTIOUS DISEASES (2022)

Add to Collection

Editorial Material Medicine, General & Internal

Oxford-AstraZeneca COVID-19 vaccine efficacy

Maria Deloria Knoll et al.

LANCET (2021)

Add to Collection

Review Immunology

The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection

Oreste Gallo et al.

Summary: This study critically reviews the latest molecular and cellular findings on the mucosal response to SARS-CoV-2 in the nasal cavity and in NALT, and analyzes its impact on the subsequent course of COVID-19. The possibility of modulating the systemic inflammatory network against the virus starting from the initial phases of the nasal and nasopharyngeal response is explored, with potential clinical and epidemiological implications for mucosal vaccine development.

MUCOSAL IMMUNOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months

Einav G. Levin et al.

Summary: A study in Israel revealed that waning immunity after receiving two doses of the BNT162b2 vaccine led to an increase in the incidence of SARS-CoV-2 infection. Levels of spike-binding IgG and neutralizing antibodies decreased more significantly in men, individuals aged 65 or older, and immunosuppressed individuals in a longitudinal study involving nearly 4000 healthcare workers.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Critical Care Medicine

Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan

Szu-Min Hsieh et al.

Summary: The phase 2 clinical trial of the MVC-COV1901 vaccine in Taiwan showed promising results in terms of safety and immunogenicity, supporting further phase 3 efficacy trials.

LANCET RESPIRATORY MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

CpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge

Chia-En Lien et al.

Summary: This study demonstrated the immunogenicity and protective effects of the MVC-COV1901 vaccine in hamster models, showing high levels of neutralizing antibodies, reduced weight loss, lung pathology, and lung viral load post-infection. Vaccination with either 1 μg or 5 μg of adjuvanted S-2P produced comparable immunogenicity and protection from infection.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Cell Biology

Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models

Neeltje van Doremalen et al.

Summary: Intranasal vaccination with ChAdOx1 nCoV-19/AZD1222 reduced viral loads in nasal swabs in vaccinated macaques and hamsters challenged with SARS-CoV-2, indicating potential for further investigation as a vaccination route for COVID-19 vaccines.

SCIENCE TRANSLATIONAL MEDICINE (2021)

Add to Collection

Article Public, Environmental & Occupational Health